Light beams to the brain: a new hope for Alzheimer's?

NCT ID NCT04784416

Ongoing Symptom relief Sponsor: NYU Langone Health Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new, non-invasive treatment called transcranial photobiomodulation (t-PBM) for people with mild cognitive impairment or early Alzheimer's disease. 196 participants aged 65-85 will receive either real or fake light therapy to the forehead for 8 weeks. The goal is to see if this light treatment can improve memory and thinking skills.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE MILD COGNITIVE IMPAIRMENT

Contacts and locations

Locations

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
NYU Langone Health

New York, New York, 10016, United States
Nathan Kline Institute

Orangeburg, New York, 10962, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.